A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
The objectives of this study were to determine (1) the expenditures of hospitals for IV histamine2-receptor antagonists (H2-RA), and (2) the cost savings that might be realized if only a single IV H2-RA was purchased for use. Forty hospitals provided data about purchase prices for each IV H2-RA dosage form purchased (cimetidine, ranitidine, and famotidine), the number of each dosage form used during the 12-month study period, purchase price and extent of usage for supplies, labor costs for preparing and administering IV H2-RAs, and IV H2-RA dosage schedules. The study showed that most hospitals were spending more money for IV H2-RAs than necessary given the pricing structures of the three products available to them at the time of this study. Also, that significant cost savings could be realized if a single H2-RA was used exclusively.
University of Florida, Gainesville 32610.
R
R
Segal
T
T
Oh
R
R
Ben-Joseph
W L
WL
Russell
D002927:Cimetidine / Q000191:economics / Q000627:therapeutic use; D003625:Data Collection; D016527:Drug Costs / Q000706:statistics & numerical data*; D017723:Drug Utilization Review / Q000191:economics*; D015738:Famotidine / Q000191:economics / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000191:economics* / Q000627:therapeutic use; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006761:Hospitals / Q000145:classification; D006801:Humans; D010607:Pharmacy Service, Hospital / Q000191:economics* / Q000706:statistics & numerical data; D011899:Ranitidine / Q000191:economics / Q000627:therapeutic use; D015144:Southeastern United States